Real world data on IO-based therapy for metastatic renal cell carcinoma

PURPOSE: Immune-based (IO)-combinations are the backbone in the systemic therapy of metastatic renal cell carcinoma (mRCC). Despite phase III clinical trial data, real world data are of special importance to reflect clinical practice. METHODS: This retrospective study included 201 mRCC patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Stühler, Viktoria, Herrmann, Lisa, Rausch, Steffen, Stenzl, Arnulf, Bedke, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314860/
https://www.ncbi.nlm.nih.gov/pubmed/35907009
http://dx.doi.org/10.1007/s00432-022-04173-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314860/
https://www.ncbi.nlm.nih.gov/pubmed/35907009
http://dx.doi.org/10.1007/s00432-022-04173-0

Ejemplares similares